-
01.16.2025 | CARB-X funds Justus Liebig University Giessen to develop antibiotic targeting Gram-negative pathogens
CARB-X will award a seed grant of US$610k to Justus Liebig University Giessen (JLU) to support the definition of a lead optimization path for the development of a direct-acting peptide therapeutic based on a natural-product scaffold targeting Gram-negative pathogens.
-
01.14.2025 | CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics $3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.07.2025 | CARB-X funds Clarametyx Biosciences to develop anti-biofilm vaccine
CARB-X will award Clarametyx Biosciences US$2.6 million to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program.
Toggle navigation